<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03768518</url>
  </required_header>
  <id_info>
    <org_study_id>NL54275.091.15</org_study_id>
    <nct_id>NCT03768518</nct_id>
  </id_info>
  <brief_title>GLP-1 Receptor Expression in CHI</brief_title>
  <acronym>GLP-1-CHI</acronym>
  <official_title>The Physiology of Glucagon-like-peptide-1 Espression in Patients With Endogenous Hyperinsulinism: Correlation With Histopathology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is the in vivo and ex vivo investigation of the expression and&#xD;
      distribution of the GLP-1R in the pancreas of CHI patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Congenital hyperinsulinism (CHI) is a rare disease of infants characterized by the presence&#xD;
      of functionally defective non-neoplastic beta-cells with inappropriate (over-) secretion of&#xD;
      insulin, leading to life-threatening hypoglycaemia. Beta cells specifically express the&#xD;
      glucagon-like-peptide-1 (GLP-1R), which could be a promising target for diagnostic and&#xD;
      therapeutic purposes. In this study we propose to investigate the physiology of GLP-1&#xD;
      receptor expression in CHI. Expression of the GLP-1 receptor will be quantified in vivo by&#xD;
      68Ga-NODAGA-exendin-4 PET/CT. This data will be compared with post-surgical autoradiography&#xD;
      and morphometric determinations.&#xD;
&#xD;
      Furthermore, we will evaluate 68Ga-exendin-4 PET/CT for the pre-operative localization of&#xD;
      foci of over-secreting beta cells in CHI and the discrimination between focal and diffuse&#xD;
      CHI. We will compare GLP-1R PET/CT to the currently used pre-operative imaging technique&#xD;
      (18F-DOPA PET combined with contrast enhanced CT). To compare these imaging techniques&#xD;
      according to sensitivity, we will analyze intra-operative findings and clinical outcomes.&#xD;
&#xD;
      These highly relevant data will allow us to evaluate the expression of GLP-1R in CHI and its&#xD;
      usefulness as a target for diagnosis of this disease. Since the localization of foci in CHI&#xD;
      and the discrimination between focal and diffuse CHI is challenging, surgical removal of&#xD;
      unnecessary large portions of the pancreas in frequently necessary. Evaluation of a better&#xD;
      target for pre-operative imaging would therefore be of great value.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      The primary objective is the in vivo and ex vivo investigation of the expression and&#xD;
      distribution of the GLP-1R in the pancreas of CHI patients. A 68Ga-NODAGA-exendin 4 PET/CT&#xD;
      will be performed in all patients included in this study. The results of quantitative imaging&#xD;
      will then be compared to GLP-1R expression and autoradiography of surgical specimens to&#xD;
      determine the interdependency of radiotracer uptake, beta cell mass and GLP-1R expression.&#xD;
&#xD;
      Furthermore, GLP-1R imaging will be compared to the standard imaging techniques now used in&#xD;
      pre-operative imaging of children with CHI. All patients will undergo the standard imaging&#xD;
      procedure, consisting of an 18F-DOPA PET scan combined with a contrast-enhanced CT. The&#xD;
      results of the GLP-1R imaging will be compared to standard imaging in respect to sensitivity&#xD;
      for localization of the lesion and discrimination between focal and diffuse CHI. This will be&#xD;
      determined by the comparison of the results of pre-operative imaging with intra-operative&#xD;
      findings.&#xD;
&#xD;
      Also, the safety (side-effects) of 68Ga-NODAGA-exendin and 18F-DOPA will be assessed.&#xD;
&#xD;
      Furthermore, dosimetric calculations will be performed and the minimum radioactivity dose of&#xD;
      68Ga-NODAGA-exendin 4 to obtain acceptable/reliable images will be determined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 7, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Expression and distribution of GLP-1R in pancreas of children with CHI</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of PET quantification with autoradiography and histology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the exendin PET/CT and F-DOPA PET/CT</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of sensitivity and specificity for localization of focal CHI</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Congenital Hyperinsulinism</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>68Ga-exendin-4 PET/CT</intervention_name>
    <description>68Ga-exendin-4 PET/CT</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumour tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients (&lt;16 years) with biochemically proven endogenous congenital hyperinsulinism&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biochemically and clinically proven endogenous congenital hyperinsulinism:&#xD;
&#xD;
          -  Unresponsive to medical treatment (diazoxide)&#xD;
&#xD;
          -  Indication for 18F-DOPA PET/CT based on mutation analysis&#xD;
&#xD;
          -  Standard imaging (18F-DOPA PET/CT) not older than 8 weeks&#xD;
&#xD;
          -  &lt;16 years old&#xD;
&#xD;
          -  Informed consent signed by parents or legal guardians of the patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Genetically proven diffuse CHI (presenting with a homozygous or compound heterozygous&#xD;
             ABCC8/KCNJ11 mutation)&#xD;
&#xD;
          -  Calculated creatinine clearance below 40 ml/min&#xD;
&#xD;
          -  Evidence of other malignancy than insulin producing tumors in conventional imaging&#xD;
             (suspicious liver, bone and lung lesions based on CT)&#xD;
&#xD;
          -  Age &gt; 16 years&#xD;
&#xD;
          -  No signed informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Gotthardt, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marti Boss</last_name>
    <phone>+31243667243</phone>
    <email>marti.boss@radboudumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marti Boss</last_name>
      <phone>+31243667243</phone>
      <email>marti.boss@radboudumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>December 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2018</study_first_posted>
  <last_update_submitted>December 6, 2018</last_update_submitted>
  <last_update_submitted_qc>December 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Radboud University</investigator_affiliation>
    <investigator_full_name>Martin Gotthardt</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Exendin</keyword>
  <keyword>GLP-1</keyword>
  <keyword>PET/CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Hyperinsulinism</mesh_term>
    <mesh_term>Hyperinsulinism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

